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Introduction
Primary cardiac tumors are rare, occurring in 0.02 to 2.8% of
autopsy series; a plurality of these cases are cardiac myxo-
mas, which account for 30 to 50% of primary cardiac tumors
in pathologic series.1 The vast majority of cardiac myxomas
—83% of cases—occur in the left atrium, while 13% occur in
the right atrium.1 Demographically, patients are diagnosed
at a mean age of 50 with nearly a 2:1 female predominance.1
Myxomas are generally benign tumors1 that are thought to
be derived from endocardial multipotent mesenchymal
cells.2,3 However, they have a higher risk of recurrence in








Abstract Background Cardiac myxomas, the most common primary cardiac tumors, are
generally benign neoplasms. Primary cardiac lymphoma is a rare cardiac malignancy
with a very poor prognosis. Here we present a case of a cardiac myxoma with cerebral
metastases and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
arising within the cerebral metastases.
Case description A 62-year-old man, who presented with symptoms of multiple
transient ischemic attacks, was found to have a left atrial myxoma. Twelvemonths after
excision of themyxoma, the patient experienced a recurrence of neurologic symptoms.
Brain magnetic resonance imaging revealedmultiple hemorrhagic masses. Craniotomy
was performed to resect the lesions. Histopathologic examination confirmed cardiac
myxoma metastases and a small lymphocytic infiltrate within the tumor consistent
with CLL/SLL.
Conclusion Including the present case, there are 27 cases of cardiac myxoma cerebral
metastases and 22 cases of lymphomas arising withinmyxomas. The present case is the
first known instance of both entities in the same patient. There is no standard
management for either cardiac myxoma metastases or lymphoma within a myxoma.
For both diseases, surgical excision is the primary treatment modality, but postopera-
tive chemotherapy and/or radiation have been attempted. Myxomas may create a
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While the most common clinical presentation of cardiac
myxomas is dyspnea secondary to congestive heart failure,4
as many as 50% of the reported cases of atrial myxomas
present with complications due to embolization, and up to
half of these cases present with neurologic manifestations.5
Among these neurologic manifestations, atrial myxomas can
cause infarction, aneurysm, or rarely metastasis.5 To date,
only 27 cases of cardiacmyxomametastasis to the brain have
been reported, including the present case.
Primary cardiac lymphoma is also particularly rare,
amounting to less than 2% of all primary cardiac tumors.3
The most common histological subtype of primary cardiac
lymphoma is large B cell lymphoma.6 Most cases of primary
cardiac lymphoma occur in immunocompromised patients.6
The outlook for these patients is generally poor—the median
survival is 7 months after initial diagnosis.6 Primary cardiac
lymphoma arising within cardiac myxoma is exceedingly rare
with only 22 reported cases since 2009, including the present
case.3,7
The present case is the first known case of myxoma
metastases and lymphoma arising within myxoma occurring
in the same patient. Additionally, it is thefirst known instance
of a lymphoma arising within cardiac myxoma metastases
rather than within the cardiac primary tumor.
Case Report
A 62-year-old male patient with a past medical history of
hypertension, hypertrophic cardiomyopathy, and an episode
of left arm numbness in April 2016 initially presented to the
hospital with mild chest discomfort, left arm numbness, visual
changes, and gait instability in June 2016. The patient under-
went stroke workup including a magnetic resonance imaging
(MRI) of thebrain,which demonstrated hemorrhagic lesions to
the brain and transesophageal echocardiography, which
revealed a 4.22.4 cm (centimeters) mass in the left atrium.
Gross total resection of the cardiac lesionwas performed under
cardiopulmonarybypass througharight thoracotomyapproach
in July of 2016. The patient had an uneventful postoperative
course. Echocardiography showed no evidence of residual
tumor. Histopathologic examination confirmed a diagnosis of
left atrial myxoma. In December 2016, the patient presented to
thehospitalwith painful fingertip nodules. Following resection
of these lesions, histopathologic evaluation proved that these
lesions were myxomatous.
The patient returned to thehospital in June 2017, 12months
after his initial presentation, complaining of 2 weeks of weak-
ness and clumsiness of the left upper extremity and episodes of
blurred vision lasting 30 to 40minutes several times a week.
Repeat transesophageal echocardiogram showed no evidence
of intracardiac recurrence. Brain MRI performed with and
without contrast demonstrated enlarged heterogeneously
enhancing hemorrhagic masses in the right posterior occipi-
tal–parietal region with increased vasogenic edema and mild
mass-effect on the posterior horn of the right lateral ventricle
(►Fig. 1). The dominant enlarging hemorrhagic lesion mea-
sured 363637mm (millimeter) and a second measured
181412mm.Threeother lesionsfrompreviousscans inthe
posterior frontal and parieto-occipital regions were
decreasing or resolved. Image-guided right parieto-occipital
craniotomy with neuromonitoring for resection of the domi-
nant and three other lesions was performed. Four tan hemor-
rhagicsoft tissuespecimensweresubmitted forhistopathologic
evaluation, which demonstratedmetastatic atrial myxoma and
a small lymphocytic lymphoma/chronic lymphocytic leukemia
arising (SLL/CLL) from within the metastatic atrial myxoma
(►Fig. 1). The atypical predominantly perivascular small lym-
phocytic infiltratewithin the tumor revealed a PAX (paired box
gene)-5þ/CD (cluster of differentiation)20-/CD5þ/CD3-/
CD23þ (partial)/BCL (B cell lymphoma)-6-/cyclin D1- immu-
nophenotype on immunoperoxidase stains (►Fig. 1). These
immunohistochemical results, together with the morphologic
features, are consistent with CLL/SLL. Therewas no evidence of
lymphoma outside the myxoma. Neither chemotherapy nor
radiotherapy was administered.
Following the procedure, the patient recovered well.
Postoperative MRI showed postoperative changes and no
evidence of residual tumor. The patient was placed on
levetiracetam prophylactically for 5 days. He initially
reported worsening visual fields on postoperative day 1,
which partially resolved by postoperative day 2. There
were no other signs or symptoms. The patient was dis-
charged on postoperative day 2 for close outpatient follow-
up. As of a 48-month follow-up visit, the patient was doing
well with continuous visual field improvement and no evi-
dence of disease.
Discussion
There are 27 cases—including the present case—of a cardiac
myxomametastasizing to the brain reported in the literature
(►Table 1).2 The authors are aware of only one other case of
histopathologically proven CLL/SLL within a cardiac myxo-
ma8 and only 21 other cases of lymphomas within a cardiac
myxoma (►Table 2).3,7 The present case also represents the
first known instance of a lymphoma arising within a myxo-
matous cerebral metastasis.
As this is the first reported case of both cardiac myxoma
metastases and lymphoma within a cardiac myxoma in the
same patient, it is unclear if the presence of lymphoma
is related to the metastatic potential of an otherwise
usually benign tumor. Cardiac myxomas are thought to
metastasize secondary to embolism prior to or during surgi-
cal handling.2 Despite this, embolic manifestations can be
delayedmonths or even years.2,13,14 This patient’s additional
presentation with myxomatous involvement of the extremi-
ties 6 months after his initial presentation supports the
theory of arterial embolization. Additionally, cardiac myxo-
mas are known to secrete several inflammatory cytokines
such as endothelin-1, interleukin-6, cysteine X cysteine
cytokines, interleukin-8, and growth-related oncogene α.46
It is also known that chronic inflammation in several inflam-
matory conditions is associated with the development of
lymphoma.47 Therefore, a more parsimonious hypothesis is
that the CLL/SLL arose within the cardiac myxoma metasta-
ses because of the chronic inflammatory state created by the
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myxoma.3,39,41,43 Given the present case’s neurologic man-
ifestations prior to diagnosis of his cardiac myxoma, it is
possible that the cerebral metastases were present several
months before they were formerly diagnosed; if so, this
longstanding inflammation would potentially allow for
malignant transformation. Laird-Fick et al8 hypothesize
that a shared genetic defect could be the link between
myxoma and CLL/SLL, noting that abnormalities on chromo-
somes 12 and 17 as well as in the protein kinase-A pathway
(including Carney complex gene mutations) have been asso-
ciated with both tumors. A recent study showed that myxo-
mas express elevated oncogenes and malignancy-related
proteins such as c-MYC, p53, vimentin, and hypoxia-induc-
ible factor 1-α compared with normal heart tissue. This
suggests that even though myxomas often clinically behave
as benign tumors, they possess latent oncogenic and meta-
static potential.48
It is also notable that lymphomas arising within cardiac
myxomas do not behave like primary cardiac lymphomas.
While most cases of primary cardiac lymphoma occur in
immunocompromised patients, all 22 reported cases of
lymphoma within myxoma occurred in immunocompetent
patients (►Table 2).6 The prognosis for lymphoma arising
within myxoma also seems to be better than the 7-month
median survival associated with primary cardiac lymphoma
(►Table 2).6However, the sample size and follow-up data are
limited so caution should be used when interpreting these
data.
Because cardiac myxomas with cerebral metastases are
extremely rare, there is no established gold standard treat-
ment (►Table 1). Surgical excision seems to be the primary
approach for diagnostic purposes, treatment of one to two
isolated brain metastases, or treatment when one of several
lesions is life-threatening.10,14 Radiation therapy can be used
as a possible alternative treatment in patients with multiple
metastases or as a supplementary treatment for patients who
do not experience resolution with surgery alone.2,12–14,18
Most often, radiotherapy consisted of palliative whole brain
radiationat25 to30Gy (Gray),2,13,14butdosesashighas40.812
and 50 Gy18 have been attempted with positive results.
Postoperative chemoradiotherapy using ifosfamide and doxo-
rubicin and postoperative chemotherapy using doxorubicin
alone have been attempted in two cases with positive and
equivocal results, respectively.2,18
Fig. 1 A magnetic resonance imaging T1-weighted image prior to gadolinium administration, demonstrated a lesion in the parieto-occipital
region (A). The T1-weighted image after gadolinium injection showed enhancement in the center of the mass (B). Fluid attenuation inversion
recovery image showed perifocal edematous changes extending to the atrium and occipital horn of the right lateral ventricle (C). Gradient echo
image amplified the artifact caused by hemorrhagic products in and around the mass (D). Microscopic examination at 2x magnification reveals
metastatic myxoma with dense lymphoid infiltrates (E and F). Further examination at 10x magnification shows the lymphoid infiltrate within
myxoma is tightly cuffing blood vessels (G). Immunohistochemistry at 10x magnification reveals Pax 5 stain positive in infiltrate indicating B cell
lineage (H), CD3 stain demonstrates only few T cells (I), CD5 stain expression in the B cell infiltrate (J), negative cyclin D1 stain excludes mantle
cell lymphoma (K), and CD23 stain is positive in the small B cell infiltrate (L).
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Additionally, the standard management of lymphomas
arisingwithin cardiacmyxomas has not yet been determined
because the cases occur so infrequently (►Table 2). While 7
out of the 22 cases have been treated with postoperative
chemotherapy, it is not clear if chemotherapy is needed in
the setting of disease confined within the myxoma status
post total resection.3 One out of the 22 cases died as a result
of chemotherapy-induced neutropenic fever and opportu-
nistic pneumonia42 and three other cases that did not receive
postoperative chemotherapy had no evidence of disease
recurrence at a six-,40 ten-,7 and eleven-36 year follow-up.
Furthermore, it is possible that the lymphoma remains
localized completely within the myxoma, and if so, it may
be prudent to withhold postsurgical chemotherapy until the
patient develops a recurrence.3,7,39–41,43 As of now, the
patient presented in this report has been treated with
surgery alone.
Further characterization of cardiac myxomas through
molecular markers might allow for a better understanding
of the pathogenesis of cardiac myxoma and myxomatous
metastases as well as more rapid diagnosis of this rare
disease. Future studies examining the potential for a related
pathogenesis between cardiac myxoma and CLL/SLL might
also improve the generalizable knowledge surrounding these
two diseases. Additional case reports and follow-up may
elucidate the most appropriate treatments for cardiac
Table 1 Reported cases of histopathologically proven cardiac myxoma metastasizing to the braina












1 Maas [our case] 2019 62 12 Fingertips Yes No No NED48
2 Rose et al case 12 2016 44 5 No No Yes No DOD17
3 Rose et al case 2 2 2016 52 0 No No No Yes AWD63
4 Badrisyah et al9 2012 15 36 No Yes No No NED72
5 Radoi et al10 2012 45 18 No Yes No No AWD12
6 Kumar et al11 2011 30 24 No Yes No No ?
7 Suzuki et al12 2008 68 6 No Yes Yes No ?
8 Moiyadi et al13 2007 35 48 No Yes Yes No AWD6
9 Altundag et al14 2005 41 15 No Yes Yes No AWD63
10 Acikel et al15 2004 58 0 No No No No ?
11 Hirundayaraj et al16 2004 50 -1 No Yes No No ?
12 Hou et al17 2001 37 10 Bone No No No DOD12
13 Bernet et al18 1998 31 2 Muscle, lung Yes Yes Yes NED120
14 Scarpelli et al19 1997 64 144 No Yes No No ?
15 Samaratunga et al20 1994 60 -7 No Yes No No NED21
16 Kanda et al21 1994 70 -7 No Yes No No NED9
17 Chozick et al22 1992 61 8 No Yes No No NED72
18 Todo et al23 1992 32 10 Jejenum No No No DOD10
19 Kotani et al24 1991 48 3 Soft tissue,
aorta
Yes No No DOD53
20 Ng et al25 1990 54 6 No Yes No No AWD18
21 de Morais et al26 1988 73 0 Kidney,
pancreas,
stomach
No No No DOD1
22 Bazin et al27 1987 56 48 No Yes No No ?
23 Kadota et al28 1987 44 3 Skin Yes No No ?
24 Markel et al29 1986 18 30 Bone No No No AWD39
25 Seo et al30 1980 36 96 Bone Yes No No AWD120
26 Budzilovich et al31 1979 52 0 No No No No DOD1
27 Rankin and DeSousa32 1978 44 96 No Yes No No AWD120
Abbreviations: AWD, alive with disease; CT, chemotherapy; DOD, died of disease; NED, no evidence of disease; RT, radiotherapy.
aAdapted from Rose et al 2016,2 Moiyadi et al 2007,13 and Altdung et al 200514; added Kumar et al11 and Suzuki et al.12
Note: “?” refers to unknown outcome.
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myxoma metastases and lymphoma with cardiac myxoma
leading to better patient outcomes.
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